NESS ZIONA, Israel, November 5, 2015 /PRNewswire/ --
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that the Company's CEO, Dr. Ron Babecoff, will be meeting with US and Canadian investors on the week of November 9-13, 2015. Over the course of that week, Dr. Babecoff will be visiting New York, Boston, Chicago and Toronto.
On December 2-3, 2015, Dr. Babecoff will be attending and presenting at the LD Micro Conference taking place at the Luxe Sunset Hotel in Los Angeles. This will provide investors located on the West Coast an opportunity to meet with management. Dr. Babecoff's presentation is scheduled for Thursday, December 3, 2015 at 8:30am Pacific Time.
On both the roadshow and the LD Micro conference there will be an opportunity for investors to meet one-on-one with Dr. Babecoff. Investors interested in meeting with management should contact the Investor Relations team at BiondVax at email@example.com.
The corporate presentation which will be used on the roadshow and at the conference is available for download from the investor relations section of BiondVax's website at http://www.biondvax.com.
About BiondVax Pharmaceuticals Ltd
BiondVax is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains.
BiondVax's technology utilizes a unique, proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes no obligation to update or revise any forward-looking statements.
For further information, please contact: Company Contact Limor Chen, Director of BD firstname.lastname@example.org Investor Relations Contact GK Investor Relations Kenny Green, Partner +1-646-201-9246 email@example.com
SOURCE BiondVax Pharmaceuticals Ltd.